Tipiracil D6

Tipiracil D6 is a deuterated form of tipiracil, which is an orally administered antineoplastic agent used in combination with other chemotherapy medications to treat patients with advanced gastrointestinal cancers. Tipiracil D6 is a stable isotope-labeled derivative of tipiracil, which helps in the identification and quantification of the parent drug in biological samples using mass spectrometry. The chemical structure of tipiracil D6 is similar to that of tipiracil, with the exception of six deuterium atoms that replace six hydrogen atoms. This modification helps in the differentiation of the drug from endogenous compounds and other medications that may interfere with its analysis. Tipiracil D6 is typically administered as part of a combination therapy with trifluridine/tipiracil for the treatment of metastatic colorectal cancer. The drug works by inhibiting thymidine phosphorylase, which is an enzyme involved in the metabolism of fluorouracil (5-FU). By inhibiting thymidine phosphorylase, tipiracil D6 enhances the therapeutic effect of 5-FU, thereby improving the overall survival of patients with advanced gastrointestinal cancers. In conclusion, tipiracil D6 is a useful tool for identifying and quantifying the parent drug in biological samples. Its use in combination therapy with trifluridine/tipiracil has shown promising results in the treatment of metastatic colorectal cancer.